Vistagen upgraded to Buy from Hold at Jefferies

Jefferies upgraded Vistagen to Buy from Hold with a price target of $15, up from 20c. The analyst says Vistagen is “poised to become a major turnaround story.” THe company’s lead asset fasedienol is a fast-acting nasal spray whose recent Phase III social anxiety data drives 50%-60% confidence in an FDA approval, the analyst tells investors in a research note.